UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

X QUARTERLY

REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended July 1, 2007

OR

TRANSITION REPORT

PURSUANT TO SECTION 13

OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition

period from________to_______

COMMISSION FILE

NUMBER 1-3619

----

PFIZER INC.

(Exact name of registrant as specified in its charter)

DELAWARE

(State of Incorporation)

13-5315170

(I.R.S. Employer Identification No.)

235

East 42nd Street, New York, New York 10017

(Address of principal executive offices) (zip

code)

(212) 573-2323

(Registrant's telephone number)

Indicate by check mark whether the registrant (1) has

filed all reports required to be filed by Section 13 or 15(d) of the

Securities Exchange Act of 1934 during the preceding 12 months (or for such

shorter period that the registrant was required to file such reports) and (2)

has been subject to such filing requirements for the past 90 days.

YES X NO

Indicate by check mark whether the registrant is a large

accelerated filer, an accelerated filer, or a non-accelerated filer. See

definition of "accelerated filer and large accelerated filer" in

Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer X

Accelerated filer Non-accelerated

filer

Indicate by check mark whether the registrant is a shell

company (as defined in Rule 12b-2 of the Exchange Act).

YES NO X

At August 1, 2007, 6,927,108,833 shares of the issuer's

voting common stock were outstanding.

FORM 10-Q

For the Quarter

Ended

July 1, 2007

Table

of Contents

PART I. FINANCIAL

INFORMATION

Page

Item 1.

Financial Statements

Condensed

Consolidated Statements of Income for the three months and six months ended July

1, 2007, and July 2, 2006

Condensed

Consolidated Balance Sheets as of July 1, 2007, and December 31, 2006

Condensed

Consolidated Statements of Cash Flows for the six months ended July 1,

2007, and July 2, 2006

Notes to

Condensed Consolidated Financial Statements

Review Report

of Independent Registered Public Accounting Firm

18

Item 2.

Management's

Discussion and Analysis of Financial Condition and Results of Operations

19

Item 3.

Quantitative

and Qualitative Disclosures About Market Risk

48

Item 4.

Controls and

Procedures

49

PART II. OTHER

INFORMATION

Item 1.

Legal

Proceedings

49

Item 1A.

Risk Factors

51

Item 2.

Unregistered

Sales of Equity Securities and Use of Proceeds

52

Item 3.

Defaults Upon

Senior Securities

52

Item 4.

Submission of

Matters to a Vote of Security Holders

52

Item 5.

Other

Information

52

Item 6.

Exhibits

53

Signature

54

PART

I - FINANCIAL INFORMATION

Item 1. Financial Statements.

PFIZER INC AND

SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(UNAUDITED)

Three

Months Ended

Six

Months Ended

(millions, except per common share

data)

July 1,

2007

July 2,

2006

July 1,

2007

July 2,

2006

Revenues

11,084

11,741

23,558

23,488

Costs and expenses:

Cost of sales(a)

2,109

1,790

3,996

3,461

Selling,

informational and administrative expenses(a)

3,844

3,881

7,205

7,276

Research and

development expenses(a)

2,165

1,742

3,830

3,285

Amortization of

intangible assets

783

823

1,598

1,648

Acquisition-related

in-process research and development charges

--

513

283

513

Restructuring

charges and acquisition-related costs

1,051

268

1,863

567

Other

(income)/deductions - net

(487)

(359)

(889)

(615)

Income from

continuing operations before provision for taxes on income and minority

interests

1,619

3,083

5,672

7,353

Provision for

taxes on income

272

790

961

1,052

Minority

interests

Income from

continuing operations

1,345

2,290

4,706

6,296

Discontinued

operations:

Income from

discontinued operations - net of tax

--

108

--

210

Gains/(losses)

on sales of discontinued operations - net of tax

(78)

17

(47)

20

Discontinued

operations - net of tax

(78)

125

(47)

230

Net income

1,267

2,415

4,659

6,526

Earnings per common share - basic:

Income from

continuing operations

0.19

0.31

0.67

0.86

Discontinued

operations - net of tax

(0.01)

0.02

(0.01)

0.03

Net income

0.18

0.33

0.66

0.89

Earnings per common share -

diluted:

Income from

continuing operations

0.19

0.31

0.67

0.86

Discontinued

operations - net of tax

(0.01)

0.02

(0.01)

0.03

Net income

0.18

0.33

0.66

0.89

Weighted-average

shares used to calculate earnings per common share:

Basic

6,966

7,282

7,009

7,298

Diluted

6,990

7,305

7,033

7,330

Cash dividends paid per common

share

0.29

0.24

0.58

0.48

(a)

Exclusive of amortization of

intangible assets, except as disclosed in Note 10B. Goodwill and

Other Intangible Assets: Other Intangible Assets.

See accompanying

Notes to Condensed Consolidated Financial Statements.

PFIZER

INC AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

(millions

of dollars)

July 1,

2007*

Dec. 31,

2006**

ASSETS

Cash and cash equivalents

2,138

1,827

Short-term investments

20,115

25,886

Accounts receivable, less allowance

for doubtful accounts

9,497

9,392

Short-term loans

540

514

Inventories

5,734

6,111

Prepaid expenses and taxes

3,564

3,157

Assets of discontinued operations and

other assets held for sale

34

62

Total current assets

41,622

46,949

Long-term

investments and loans

5,067

3,892

Property, plant and equipment, less

accumulated depreciation

16,298

16,632

Goodwill

20,985

20,876

Identifiable

intangible assets, less accumulated amortization

22,902

24,350

Other assets,

deferred taxes and deferred charges

3,529

2,138

Total assets

110,403

114,837

LIABILITIES

AND SHAREHOLDERS' EQUITY

Short-term borrowings, including

current portion of long-term debt

2,432

2,434

Accounts payable

1,845

2,019

Dividends payable

2,010

2,055

Income taxes payable

516

6,466

Accrued compensation and related

items

1,573

1,903

Other current liabilities

6,760

6,510

Liabilities of discontinued operations

and other liabilities held for sale

--

Total current liabilities

15,136

21,389

Long-term debt

5,777

5,546

Pension benefit

obligations

3,389

3,632

Postretirement

benefit obligations

1,955

1,970

Deferred taxes

7,602

8,015

Other taxes

payable

5,426

--

Other

noncurrent liabilities

3,024

2,927

Total liabilities

42,309

43,479

Shareholders' equity

Preferred stock

110

141

Common stock

442

441

Additional

paid-in capital

69,555

69,104

Employee

benefit trust, at fair value

(604)

(788)

Treasury stock

(51,833)

(46,740)

Retained

earnings

50,304

49,669

Accumulated

other comprehensive income/(expense)

120

(469)

Total shareholders' equity

68,094

71,358

Total liabilities and shareholders'

equity

110,403

114,837

* Unaudited.

** Condensed from audited

financial statements.

See accompanying

Notes to Condensed Consolidated Financial Statements.

PFIZER INC AND

SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

Six Months

Ended

(millions of dollars)

July 1,

2007

July 2,

2006

Operating

Activities:

Net income

4,659

6,526

Adjustments to

reconcile net income to net cash provided by operating activities:

Depreciation

and amortization

2,712

2,694

Share-based

compensation expense

228

326

Acquisition-related

in-process research and development charges

283

513

Gains on

disposal of investments, products and product lines

(79)

(168)

(Gains)/losses

on sales of discontinued operations

39

(31)

Deferred taxes

from continuing operations

(951)

(438)

Other deferred

taxes

--

45

Other non-cash

adjustments

37

270

Changes in assets

and liabilities (net of businesses acquired and divested)

(2,020)

(633)

Net cash provided by operating

activities

4,908

9,104

Investing Activities:

Purchases of

property, plant and equipment

(757)

(887)

Purchases of short-term

investments

(10,738)

(5,663)

Proceeds from

redemptions of short-term investments

17,101

13,239

Purchases of

long-term investments

(1,243)

(248)

Proceeds from redemptions

of long-term investments

22

47

Purchases of

other assets

(82)

(78)

Proceeds from

sales of other assets

29

Proceeds from

the sales of businesses, products and product lines

14

14

Acquisitions,

net of cash acquired

(463)

(1,989)

Other investing

activities

(336)

(116)

Net cash provided by investing

activities

3,547

4,322

Financing Activities:

Increase in

short-term borrowings, net

78

938

Principal

payments on short-term borrowings

(763)

(10,583)

Proceeds from

issuances of long-term debt

1,243

1,054

Principal

payments on long-term debt

(60)

(2)

Purchases of

common stock

(4,999)

(2,000)

Cash dividends

paid

(4,040)

(3,468)

Stock option

transactions and other

383

318

Net cash used

in financing activities

(8,158)

(13,743)

Effect of exchange-rate

changes on cash and cash equivalents

14

(9)

Net increase/(decrease)

in cash and cash equivalents

311

(326)

Cash and cash

equivalents at beginning of period

1,827

2,247

Cash and cash

equivalents at end of period

2,138

1,921

Supplemental

Cash Flow Information:

Cash paid

during the period for:

Income taxes

3,672

921

Interest

354

414

See

accompanying Notes to Condensed Consolidated Financial Statements.

PFIZER

INC AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 1. Basis of

Presentation

We prepared the condensed

consolidated financial statements following the requirements of the Securities

and Exchange Commission (SEC) for interim reporting. As permitted under those

rules, certain footnotes or other financial information that are normally

required by accounting principles generally accepted in the United States of

America (GAAP) can be condensed or omitted. Balance sheet amounts and operating

results for subsidiaries operating outside the U.S. are as of and for the

three-month and six month periods ended May 27, 2007, and May 28, 2006.

We made certain reclassifications to prior

period amounts to conform to the second-quarter 2007 presentation.

Revenues, expenses, assets and

liabilities can vary during each quarter of the year. Therefore, the results

and trends in these interim financial statements may not be representative of

those for the full year.

We are responsible for the unaudited

financial statements included in this document. The financial statements

include all normal and recurring adjustments that are considered necessary for

the fair presentation of our financial position and operating results.

The information included in this

Quarterly Report on Form 10-Q should be read in conjunction with the

consolidated financial statements and accompanying notes included in Pfizer's

Annual Report on Form 10-K for the year ended December 31, 2006.

Note 2. Adoption of New

Accounting Policy

As of January 1, 2007, we adopted the provisions of Financial Accounting

Standards Board (FASB) Interpretation No. 48 (FIN 48), Accounting for

Uncertainty in Income Taxes, an interpretation of SFAS 109, Accounting for

Income Taxes, and supplemented by FASB Financial Staff Position FIN

48-1, Definition of Settlement in FASB Interpretation No. 48, issued May

2, 2007, and changed our policy related to the accounting for income tax

contingencies. To understand the cumulative effect of these accounting changes,

see Note 6A. Taxes on Income: Adoption of New Accounting

Standard.

We continue to account for income tax

contingencies using a benefit recognition model. Beginning January

1, 2007, if we consider that a tax position is 'more likely than not' of being

sustained upon audit, based solely on the technical merits of the position, we

recognize the benefit. We measure the benefit by determining the amount that is

greater than 50% likely of being realized upon settlement, presuming that the

tax position is examined by the appropriate taxing authority that has full

knowledge of all relevant information. These assessments can be complex and we

often obtain assistance from external advisors.

Under the benefit recognition model, if our initial assessment

fails to result in the recognition of a tax benefit, we regularly monitor our

position and subsequently recognize the tax benefit: (i) if there are changes

in tax law or analogous case law that sufficiently raise the likelihood of

prevailing on the technical merits of the position to more likely than not; (ii)

if the statute of limitations expires; or (iii) if there is a completion of an

audit resulting in a favorable settlement of that tax year with the appropriate

agency.

Liabilities associated with uncertain tax positions are now classified as

current only when we expect to pay cash within the next 12 months. Interest and

penalties, if any, continue to be recorded in Provision for taxes on income

and are classified on the balance sheet with the related tax liability.

Prior to 2007, our policy had been to account for income tax

contingencies based on whether we determined our tax position to be 'probable'

under current tax law of being sustained, as well as an analysis of potential

outcomes under a given set of facts and circumstances. In addition, we

previously considered all tax liabilities as current once the associated tax

year was under audit.

Note 3. Acquisitions

In the first quarter of 2007, we

acquired BioRexis Pharmaceutical Corp., a privately held biopharmaceutical

company with a number of diabetes candidates and a novel technology platform

for developing new protein drug candidates, and Embrex, Inc., an animal health

company that possesses a unique vaccine delivery system known as Inovoject, which

enables baby chicks to be vaccinated while inside their eggs. In connection

with these and other small acquisitions, we recorded $283 million, in Acquisition-related

in-process research and development charges in the first quarter of 2007.

In the second quarter of 2006, we completed the acquisition of all the

outstanding shares of Rinat Neuroscience Corp., a biologics company with

several new central-nervous-system product candidates. In connection with this

and other smaller acquisitions, we recorded $513 million, in Acquisition-related

in-process research and development charges in the second quarter of 2006.

On February 28, 2006, we completed

the acquisition of the sanofi-aventis worldwide rights, including patent rights

and production technology, to manufacture and sell Exubera, an inhaled form of

insulin for use in adults with type 1 and type 2 diabetes, and the

insulin-production business and facilities located in Frankfurt, Germany,

previously jointly owned by Pfizer and sanofi-aventis, for approximately $1.4 billion

(including transaction costs). In 2006, in connection with the acquisition, as

part of our final purchase price allocation, we recorded $1.0 billion of

developed technology rights, $218 million of inventory and $166 million

of Goodwill, all of which have been allocated to our Pharmaceutical segment.

The amortization of the developed technology rights is primarily included in Cost

of sales. Prior to the acquisition, in connection with our collaboration

agreement with sanofi-aventis, we recorded a research and development milestone

due to us from sanofi-aventis of $118 million ($71 million, after

tax) in the first quarter of 2006 in Research and development expenses

upon the approval of Exubera in January 2006 by the Food and Drug

Administration (FDA).

Note 4. Discontinued

Operations

The following amounts, primarily related

to our Consumer Healthcare business which was sold in December 2006 for $16.6 billion,

have been segregated from continuing operations and included in Discontinued

operations - net of tax in the condensed consolidated statements of income:

Three

Months Ended

Six

Months Ended

(millions

of dollars)

July 1,

2007

July 2,

2006

July 1,

2007

July 2,

2006

Revenues

--

1,027

--

1,946

Pre-tax income

--

160

--

315

Provision for

taxes on income

--

(52)

--

(105)

Income from operations

of discontinued businesses - net of tax

--

108

--

210

Pre-tax gains/(losses) on sales of

discontinued businesses

(79)

26

(39)

31

Provision for taxes on gains

(9)

(8)

(11)

Gains/(losses)

on sales of discontinued operations - net of tax

(78)

17

(47)

20

Discontinued operations - net of

tax

(78)

125

(47)

230

For a period of time, we will

continue to generate cash flows and to report income statement activity in

continuing operations that are associated with our former Consumer Healthcare

business. The activities that give rise to these impacts are transitional in

nature and generally result from agreements that ensure and facilitate the

orderly transfer of business operations to the new owner. Included in

continuing operations for the second quarter of 2007 were the following amounts

associated with these transition service agreements that will no longer occur

after the full transfer of activities to the new owner: Revenues of $50 million;

Cost of sales of $45 million; Selling, informational and

administrative expense of $5 million; and Other

(income)/deduction-net of $7 million in income, and for the first six

months of 2007: Revenues of $94 million; Cost of sales of $80 million;

Selling, informational and administrative expense of $7 million; and

Other (income)/deduction-net of $9 million in income.

Note 5. Adapting to

Scale Productivity Initiative

We incurred the following costs in

connection with our Adapting to Scale (AtS) productivity initiative, which was launched

in early 2005 and broadened in October 2006:

Three

Months Ended

Six

Months Ended

(millions

of dollars)

July 1,

2007

July 2,

2006

July 1,

2007

July 2,

2006

Implementation

costs(a)

317

180